Evaluation of dopamine transporter gene variations in Turkish children with attention deficit hyperactivity disorder treated with methylphenidate adverse effects

PHARMACOGENOMICS · Published 2026-07-24 · DOI 10.1080/14622416.2026.2706504

Free full text

Authors (7)

Kubra Cigdem Pekkoc-Uyanik, Melik Yigit Bayindir, Muhammet Fatih Akdemir, Aybike Aydin Okuyan, Mahmut Cem Tarakcioglu, Sibel Ozyazgan, Zeynep Gizem Todurga Seven

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Pekkoc-Uyanik, K., Bayindir, M., Akdemir, M., et al. (2026). Evaluation of dopamine transporter gene variations in Turkish children with attention deficit hyperactivity disorder treated with methylphenidate adverse effects. PHARMACOGENOMICS. https://doi.org/10.1080/14622416.2026.2706504

Related articles

• Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology · Genetics in Medicine · 2015 · Cites or is cited by this article
• How to implement pre-emptive pharmacogenetic testing in the acute hospital setting · PHARMACOGENOMICS · 2025 · Same journal
• Opportunities and challenges for the implementation of pharmacogenomics in supportive care for gastrointestinal cancer patients in Zimbabwe · PHARMACOGENOMICS · 2025 · Same journal
• ADIPOQ genotypes and haplotypes, circulating adiponectin levels and responsiveness to antihypertensive therapy in preeclampsia · PHARMACOGENOMICS · 2025 · Same journal
• UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients · PHARMACOGENOMICS · 2025 · Same journal
• Pharmacogenomic testing for Prader-Willi syndrome: a mixed methods analysis of caregiver experiences and utilization · PHARMACOGENOMICS · 2025 · Same journal
• Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes · PHARMACOGENOMICS · 2025 · Same journal
• Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitis · PHARMACOGENOMICS · 2025 · Same journal
• Antiplatelet therapy in high-bleeding risk patients with acute coronary syndrome: pharmacogenomics in the era of precision medicine · PHARMACOGENOMICS · 2026 · Same journal
• Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use · PHARMACOGENOMICS · 2026 · Same journal